Capricor Therapeutics Inc (NASDAQ:CAPR) Files An 8-K

Capricor Therapeutics Inc (NASDAQ:CAPR), a Delaware corporation, posted to the “Investors” section of the Company’s website at www.capricor.com a corporate presentation providing an update of the Company’s current business and products (the “Corporate Presentation”). A copy of the Corporate Presentation is attached hereto as Exhibit 99.1 and is incorporated by reference into this Item 7.01 of this Current Report on Form 8-K.

Story continues below

 

Also on October 5, 2016, the Company issued a press release announcing completion of the enrollment of its ALLSTAR Phase II clinical trial. A copy of the press release is attached hereto as Exhibit 99.2 and is incorporated by reference into this Item 7.01 of this Current Report on Form 8-K.

 

The information contained in this Current Report on Form 8-K (including Exhibits 99.1 and 99.2 attached hereto) is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

An ad to help with our costs